GWPH

EPIDIOLEX® (cannabidiol)

Dravet syndrome

Quarterly Sales (Approved)

Exp Date

February 26, 2021 (Est)

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: EPIDIOLEX® (cannabidiol) for Dravet syndrome - Quarterly Sales (Approved)


WHAT IS THE CATALYST EVENT?

  • Quarterly Sales (Approved)


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • February 26, 2021 (Est)


PRIOR DATA/EVENTS

PRESS RELEASE


List last quarter's sales e.g. $137.1 million Q3/2020

2020 Revenue guidance: NOT PROVIDED by company

MECHANISM OF ACTION

  • The precise mechanisms by which EPIDIOLEX exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors.

MARKET

  • Dravet syndrome is a rare, severe, lifelong form of epilepsy that typically begins in the first year of life with frequent and/or prolonged seizures.2 Previously known as severe myoclonic epilepsy in infancy (SMEI), it affects between 1 in 20,000 to 1 in 40,000 people.3,4 About 80 percent of people with this syndrome have a gene mutation that causes problems in the way the brain works.

  • Children with Dravet syndrome can develop many different seizure types and approximately 15 percent die within 10 years of diagnosis due to issues such as SUDEP (sudden unexpected death in epilepsy), prolonged seizures (status epilepticus), seizure-related accidents such as drowning, or infections.2,5 Additionally, the majority will develop moderate to severe intellectual and developmental disabilities6 and require lifelong supervision and care.

Updated by HC

GWPH, Dravet syndrome, EPIDIOLEX® (cannabidiol), epilepsy,  seizures, rare disease

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon